Effects of Sildenafil in Resistant Hypertensives and Genetic Polymorphism

• Status: Completed
• Trial end date: 2012-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Sildenafil citrate slightly reduces blood pressure in treated hypertensives patients. However, it is unknown if the simultaneous use of sildenafil plus, at least, 3 classes of antihypertensive agents in patients with resistant arterial hypertension may have a synergic effect on the patients blood pressure. Moreover, sildenafil improves the endogen nitric oxide effects. The nitric oxide is an important signaling molecule in the body that contributes to vessel homeostasis by inhibiting vascular smooth muscle contraction and growth. Hypertension often impaired NO pathways. Nitric oxide is produced by an enzyme, called nitric oxide synthase (NOS3), that show some genetics variants, which means that this enzyme can be different from person to person. Therefore, the objective of the present study is to examine the influence of a genetic variant (known to affect NOS3 levels) in sildenafil acute effects on hemodynamic and cardiovascular function. The investigators hypothesis is that individuals with the genetic variant associated to higher levels of NOS3 will have more benefits from sildenafil treatment.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Campinas, Brazil
• Collaborator: Fundação de Amparo à Pesquisa do Estado de São Paulo
• Treatments: Nitric Oxide; Sildenafil Citrate

Criteria

Inclusion Criteria:

• resistant hypertensive (according to Resistant Hypertension - AHA Statement - 2008);

• compliance with antihypertensive treatment;

• age >35 years;

• diastolic dysfunction

Exclusion Criteria:

• valvulopathy

• decompensated heart failure

• important cardiac arrhythmias

• nephropathy

• hepatopathy

• autoimmune disease

• tabagism

• decompensated diabetes

• uncontrolled dislipidemia